PGEN Stock Recent News
PGEN LATEST HEADLINES
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of -140% and 67.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to buy for under $3 The post Penny Stocks To Buy Now: 3 To Watch Under $3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Today, we circle back on Precigen, a biotech firm that was once part of Intrexon. Precigen is advancing several drug candidates in its pipeline and recently agreed to a divesture than significantly bolstered its financial situation.
Precigen, Inc. (NASDAQ:PGEN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen Sabzevari - President and Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Nick Abbott - Wells Fargo Securities, LLC Jason Butler - JMP Securities, LLC Jennifer Kim - Cantor Fitzgerald & Co. Operator Good day, and welcome to the Precigen Second Quarter and First Half 2022 Financial Results Conference Call. After today's presentation, there will be an opportunity to ask questions.
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Yesterday, Precigen Inc (NASDAQ: PGEN) agreed to sell its non-healthcare subsidiary to URUS. HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe management deserves much credit, especially against the backdrop of the.
Precigen Inc (NASDAQ: PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-.
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?